Avax Technologies Inc.
AVXT
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.89K
Close$
Share Statistics
| Market cap | $6,894.00 |
|---|---|
| Enterprise Value | $1.31 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.05 |
| Beta | -55.48 |
| Outstanding Shares | 141,555,545 |
Return
| Return on Equity | 353.75% |
|---|---|
| Return on Assets | -539.66% |
| Return on Invested Capital | 360.47% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | -0.07 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 1.79 |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.26 |
| Debt to Equity | -0.79 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Avax Technologies Inc.
Avax Technologies, Inc is a Philadelphia based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006,...